| Prev Close | 15.42 |
| Open | 15.43 |
| Day Low/High | 15.29 / 15.62 |
| 52 Wk Low/High | 7.35 / 14.35 |
| Volume | 283.82K |
| Avg Volume | 1.22M |
| Exchange | NASDAQ |
| Shares Outstanding | 149.59M |
| Market Cap | 2.27B |
| EPS | -0.60 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 2,249,386 share increase in total short interest for Ironwood Pharmaceuticals Inc , to 16,348,161, an increase of 15.95% since 07/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The Cambridge, Mass.-based firm clinched FDA approval for hyperuricemia drug Duzallo.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced DUZALLO was approved by the U.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its second quarter 2017 results and recent business activities.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2017 investor update conference call and webcast at 4:30 p.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, announced positive top-line data from a Phase IIb clinical trial evaluating IW-3718 in adult patients with uncontrolled...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 38 th Annual Global Healthcare Conference on Thursday, June 15, 2017 at 10:00 a.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Jefferies Healthcare Conference on Thursday, June 8, 2017 at 4:00 p.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 17, 2017 at 1:00 p.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, this week presented clinical data on the effect of linaclotide on abdominal pain in irritable bowel syndrome with constipation (IBS-C)...
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotechnology company, today provided an update on its first quarter 2017 results and recent business activities.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company and its collaborators will present clinical and preclinical data for linaclotide and linaclotide...
Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the June 16th expiration.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2017 investor update conference call and webcast at 8:30 a.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the appointment of Christopher Wright, M.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 16, 2017 at 10:45 a.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotechnology company, is hosting an R&D Day today, Thursday, March 9, 2017, beginning at 9:00 a.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Cowen and Company 37 th Annual Health Care Conference on Monday, March 6, 2017 at 2:00 p.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will host a live webcast of its R&D Day on Thursday, March 9, 2017 beginning at 9:00 a.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2016 results and recent business activities.
Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.
In recent trading, shares of Ironwood Pharmaceuticals Inc. have crossed above the average analyst 12-month target price of $16.25, changing hands for $16.38/share.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2016 investor update conference call and webcast at 4:30 p.
Ironwood Pharmaceuticals, Rigel Pharmaceuticals and FibroGen were among the biotech stock movers in premarket trading on Monday.
Astellas Pharma Inc. (TSE:4503) and Ironwood Pharmaceuticals, Inc.
New bowel drug Trulance will be available for patients later this quarter.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today detailed strong execution against its strategy of building a top-performing commercial biotechnology company generating rapid, sustainable, high-margin growth.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the appointment of Amy Schulman to its board of directors.
